

GLAND PHARMA LIMITED

July 28, 2023

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Conclusion of US FDA Inspection at VSEZ Sterile Oncology Facility, Visakhapatnam

This is to inform you that the United States Food and Drug Administration (US FDA) has conducted Good Manufacturing Practice (GMP) Inspection at the Company's VSEZ Sterile Oncology Facility at Visakhapatnam between 20th July, 2023 and 28th July, 2023.

The inspection was concluded with Zero 483 observations and a classification of No Action Indicated (NAI).

Request to take the above information on record.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi Company Secretary and Compliance Officer

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India Tel: +91-40-30510999 Fax: +91-40-30510800